Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2010.0142
OPINION
|
Colorectal cancer targeted treatment: advances and resistance
|
Prof. Claus-Henning Köhne , M.D, PhD.
|
Affiliation: Prof. Claus-Henning Köhne. Klinik für Onkologie/Hämatologie, Klinikum Oldenburg, Dr.-Eden-Strasse 10, Oldenburg, Germany.
|
ABSTRACT
Genotyping-based selection of patients with wild-type metastatic colorectal cancer (mCRC) with mostly cetuximab or panitumumab has provided positive results in several phase III randomized controlled trials (RCTs). But whether these tumor-guided drugs added to chemotherapy can provide an overall survival benefit is unclear. Most RCTs have demonstrated mainly a progression-free survival gain but not an overall survival benefit. This may limit the expectations for the clinical success of these agents in the adjuvant treatment of patients with stage II or III colorectal cancer. Here, the results of clinical trials are analyzed and potential solution by combining several targeted drugs to create a potent cancer-fighting cocktail and considering rise in adverse effects are discussed.
(Citation: Gastric & Breast Cancer 2010
Oct ; 9(4):
186-192)
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €33 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
